Surrozen (SRZN) Common Equity (2020 - 2026)
Surrozen (SRZN) posted quarterly Common Equity of -$278.1 million for Q1 2026, down 5002.13% year-over-year from $5.7 million in Q1 2025, and down 48.14% quarter-over-quarter from -$187.8 million in Q4 2025.
Surrozen (SRZN) Common Equity (2020 - 2026) Analysis & Trends
Surrozen's Common Equity history runs 7 years deep, the most recent figure standing at -$278.1 million for Q1 2026.
- In Q1 2026, Common Equity fell 5002.13% year-over-year to -$278.1 million; the TTM figure through Mar 2026 stood at -$278.1 million (down 5002.13% YoY), while the FY2025 annual figure was -$187.8 million, down 778.21% from the prior year.
- Common Equity for Q1 2026 stood at -$278.1 million, down from -$187.8 million in the prior quarter.
- The five-year high for Common Equity was $102.7 million in Q1 2022, with the low at -$278.1 million in Q1 2026.
- The 5-year median for Common Equity is $37.9 million (2023), against an average of $7.7 million.
- The sharpest annual moves came in 2025 and 2026: Common Equity jumped 677.2% in 2025, then sank 5002.13% in 2026.
- Surrozen's Common Equity stood at $76.0 million in 2022, then slumped by 50.09% to $37.9 million in 2023, then sank by 156.36% to -$21.4 million in 2024, then slumped by 778.21% to -$187.8 million in 2025, then slumped by 48.14% to -$278.1 million in 2026.
- Business Quant data shows SRZN's Common Equity at -$278.1 million in Q1 2026, -$187.8 million in Q4 2025, and -$23.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Surrozen | 281.63 Mn | 281.63 Mn | - | -218.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -218.67 Mn |
| Mar 31, 2026 | -278.15 Mn |
| Dec 31, 2025 | -187.76 Mn |
| Sep 30, 2025 | -23.52 Mn |
| Jun 30, 2025 | 47.11 Mn |
| Mar 31, 2025 | 5.67 Mn |
| Dec 31, 2024 | -21.38 Mn |
| Sep 30, 2024 | 5.67 Mn |
| Jun 30, 2024 | 6.06 Mn |
| Mar 31, 2024 | 30.14 Mn |
| Dec 31, 2023 | 37.94 Mn |
| Sep 30, 2023 | 45.53 Mn |
| Jun 30, 2023 | 55.06 Mn |
| Mar 31, 2023 | 63.04 Mn |
| Dec 31, 2022 | 76.00 Mn |
| Sep 30, 2022 | 77.49 Mn |
| Jun 30, 2022 | 89.70 Mn |
| Mar 31, 2022 | 102.66 Mn |
| Dec 31, 2021 | 109.70 Mn |
| Sep 30, 2021 | 123.73 Mn |